| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-005 | 湖南九典制药股份有限公司 关于控股股东、实际控制人、董事长增持股份计划实施完成的公告 公司控股股东、实际控制人、董事长朱志宏先生保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、增持计划的基本情况：湖南九典制药股份有限公司（以下简称"公司"） 控股股东、实际控制人、董事长朱志宏先生计划自 2025 年 1 月 20 日起 6 个月内 以自有资金通过深圳证券交易所集中竞价交易的方式增持公司股份，拟增持总金 额不低于人民币 1,000 万元（含本数）且不超过 2,000 万元（含本数）。 2、增持计划的实施情况：2025 年 1 月 20 日至 1 月 21 日，朱志宏先生通过 深圳证券交易所以集中竞价交易方式累计增持 1,200,000 股，占公司总股本的 0.24%，增持总金额为 18,892,520 元， ...

Core Viewpoint - The company, Jiutian Pharmaceutical, announced that its controlling shareholder and chairman, Zhu Zhihong, plans to increase his stake in the company through the Shenzhen Stock Exchange within six months, with a total investment amount between 10 million and 20 million yuan [1] Group 1 - The controlling shareholder and actual controller of the company is Zhu Zhihong [1] - The planned share purchase will be conducted through centralized bidding on the Shenzhen Stock Exchange [1] - The total amount for the share buyback is set to be no less than 10 million yuan and no more than 20 million yuan [1]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-003 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于控股股东、实际控制人、董事长增持股份计划的公告 公司控股股东、实际控制人、董事长朱志宏先生保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 湖南九典制药股份有限公司（以下简称"公司"）控股股东、实际控制人、 董事长朱志宏先生计划自本公告披露日起 6 个月内以自有资金通过深圳证券交 易所系统采用集中竞价交易的方式增持公司股份，拟增持总金额不低于人民币 1,000 万元（含本数）且不超过 2,000 万元（含本数）。 增持计划实施的不确定风险：本次增持计划可能存在因资本市场情况发生变 化或目前尚无法预判的其他风险因素导致增持计划的实施无法达到预期的风险。 如增持计划实施过程中出现相关风险情形，公司将及时履行信息披露义务。 一、计划增持主体的基本情况 1、计划增持主体：公司控股股东、实际 ...

Group 1: Sales Performance - The sales volume of Loxoprofen Sodium Gel Patches has shown significant growth, with a positive operational trend [2] - The market size for external patch agents in 2023 is approximately ¥203.64 billion, with hospitals accounting for 69.89% and retail for 30.11% [2] Group 2: Pricing and Cost Reduction - The winning bid price for Loxoprofen Sodium Gel Patches in the Guangdong Alliance and "3+N" regions is ¥18.19 per patch, with a price reduction of about 25% [3] - In Zhejiang and Yunnan provinces, the winning bid price is ¥17.37 per patch, with a price reduction of approximately 28% [3] Group 3: Future Product Development - The company plans to enhance its sales strategy by increasing resources for the external market and building the "JiuYue" brand [3] - Expected approvals for new patch products include Indomethacin Gel Patch and Flurbiprofen Gel Patch in 2025, and Loxoprofen Sodium Patch and Ketoprofen Patch in 2026 [3] Group 4: Corporate Strategy and Governance - The company aims to expand sales channels, particularly in the external market, while enhancing brand influence [4] - There are plans to implement an employee stock incentive program to align employee interests with company growth [3] - The company is focused on increasing R&D efforts and optimizing production processes to ensure efficient operations and good returns for shareholders [4]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-001 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于 2024 年第四季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会证监许可〔2023〕526 号文同意注册，公司于 2023 年 9 月 15 日向不特定对象发行了 360.00 万张可转债，每张面值 100 元，发行总 额为 36,000.00 万元。 经深圳证券交易所（以下简称"深交所"）同意，公司可转债于 2023 年 10 月 13 日起在深交所挂牌交易，债券简称：九典转 02，债券代码：123223。 根据《深圳证券交易所创业板股票上市规则》和《湖南九典制药股份有限公 司创业板向不特定对象发行可转换公司债券募集说明书》的规定，公司可转债的 转股期限自 2024 年 3 月 21 日起至 2029 年 9 月 14 日止。 二、可转债转股及股份变动情况 1、九典转02 ...

Summary of Conference Call Company and Industry Involved - The conference call primarily discusses the pharmaceutical industry, focusing on companies involved in drug development and clinical trials, particularly in the context of regulatory approvals and market competition. Key Points and Arguments 1. **Regulatory Concerns**: The market is primarily worried about two issues: the approval process for new drugs and the actions of competitors in submitting production applications. The recent submission by Wan Gao for production approval has raised concerns among investors [1][2][3]. 2. **Clinical Trial Updates**: Companies are actively engaging with the Center for Drug Evaluation (CDE) regarding their clinical trial submissions. There is a consensus that complex drug types require extensive clinical trials, and many companies are currently conducting these trials [4][6]. 3. **Market Dynamics**: The discussion highlights the competitive landscape, particularly regarding the introduction of generic drugs. Companies are preparing for potential competition from new entrants in the market, which could impact their sales [9][32]. 4. **Pricing Strategies**: The company emphasizes adherence to national pricing guidelines and the importance of maintaining reasonable distribution costs. This is crucial to avoid issues related to pricing regulations [7]. 5. **Future Growth Expectations**: The company anticipates significant growth in the outpatient market, with plans to expand its product offerings and marketing strategies. There is a target to double sales in the outpatient sector by 2025 [10][12]. 6. **Investment in R&D**: The company is committed to enhancing its research and development capabilities, with a focus on developing new products that can be quickly commercialized. This includes expanding its product line and improving production processes [16][17]. 7. **Clinical Trial Costs**: The estimated cost for conducting large-scale clinical trials is around 20 million, with additional investments required for facility upgrades and equipment [11]. 8. **Market Positioning**: The company believes it has a competitive advantage due to its established production capabilities and a comprehensive sales team across various channels, including hospitals and clinics [33][34]. Other Important but Possibly Overlooked Content 1. **Challenges in Consistency**: There are significant challenges in achieving consistency in drug formulations, particularly with complex ingredients. This has been a point of contention in regulatory discussions [14][15][27]. 2. **Regulatory Guidance**: The lack of clear regulatory guidelines from the CDE has created uncertainty in the approval process, leading to fluctuations in stock prices based on market speculation [25][26]. 3. **International Comparison**: The call discusses differences in regulatory approaches between China, the US, and Japan, particularly regarding the approval of topical medications and the requirements for demonstrating bioequivalence [21][22][30]. This summary encapsulates the critical discussions and insights shared during the conference call, providing a comprehensive overview of the company's current standing and future outlook in the pharmaceutical industry.

市场有反馈江苏万高药业有限公司氟比洛芬凝胶贴膏上市申请获受理，但是否获批还没结果，市场（股 价）可能引起了波动。 财联社12月30日电，九典制药12月30日低开低走，盘中放量大跌。 上述人士称，我们认为没有影响，但市场情绪不好判断。 对于股价下跌，有关人士表示，公司经营一切正常。 同时，该人士向记者介绍，若后续上市，氟比洛芬凝胶贴膏并非公司独家产品，北京泰德制药也有相关 产品。 对此，记者以投资人身份联系了九典制药投资者关系部门。 那么，万高药业氟比洛芬凝胶贴膏上市获受理对九典制药有何影响？ (21财经) ...

Group 1: Company Overview - The company is Hunan Jiudian Pharmaceutical Co., Ltd., with stock code 300705 and bond code 123223 [1] Group 2: Investor Relations Activity - The investor relations activity took place on December 25, 2024, from 1:00 PM to 2:30 PM in the company meeting room [2] - Representatives from Huayuan Securities and ICBC Credit Suisse participated, totaling 4 individuals [2] Group 3: Product Sales and Market Strategy - The sales strategy for various products includes both hospital and outpatient channels, with a focus on increasing sales volume for the Loxoprofen Sodium Gel Patch [2] - The Ketoprofen Gel Patch is included in the national medical insurance drug list, primarily focusing on hospital sales, while online sales are minimal [2] - The newly launched anti-inflammatory pain relief patch primarily utilizes OTC channels for sales [3] Group 4: Research and Development - The company is developing a traditional Chinese medicine product, the Jiao Qi She Gel Patch, expected to complete clinical research in 1-2 years for re-application [2] - Current R&D focuses on generic drugs, with an emphasis on high-end formulations and innovative transdermal delivery systems [2] - Future plans include a shift towards innovative drugs, supported by a foundation of generic drugs [2] Group 5: Product Differentiation - Key differences between gel patches and adhesive patches include formulation type, matrix materials, and preparation processes [3] - Gel patches are expected to be more comfortable and skin-friendly, while adhesive patches offer better adhesion for active areas [3] - Anticipated approvals for external preparations include Indomethacin Gel Patch and Flurbiprofen Gel Patch by 2025, and Loxoprofen Sodium Patch and Ketoprofen Patch by 2026 [3] Group 6: Market Expansion and Future Plans - The company plans to expand its outpatient market by collaborating with chain pharmacies, targeting provinces such as Yunnan, Guangdong, Hunan, Sichuan, Hebei, and Gansu for OTC sales of Loxoprofen Sodium Gel Patch [5] - Potential products for future centralized procurement include Dimethicone Emulsion, Indobufen Tablets, Lansoprazole Enteric-Coated Capsules, Dapagliflozin Tablets, Ferrous Succinate Tablets, and Nicorandil Tablets [3] Group 7: Employee Incentives - The company plans to introduce an employee stock incentive plan to enhance governance and align interests between the company and core employees, thereby boosting employee motivation [4]

西部证券股份有限公司 关于湖南九典制药股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐机构名称：西部证券股份有限公司 被保荐公司简称：九典制药 | | | | | | | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：江伟 联系电话：0731-84727299 | | | | | | | 保荐代表人姓名：徐飞 联系电话：0731-84727299 | | | | | | | 现场检查人员姓名：江伟、阳欢欢 | | | | | | | 现场检查对应期间：2024 年度 | | | | | | | 现场检查时间：2024 年 12 月 10 日-2024 年 月 11 日、2024 年 12 月 16 | 12 | 日 | | | | | 一、现场检查事项 现场检查意见 | | | | | | | （一）公司治理 是 否 | | 不适用 | | | | | 现场检查手段： | | | | | | | （1）对上市公司董事、高级管理人员及有关人员进行访谈； | | | | | | | （3）查阅历次董事会、监事会、股东大会会议材料，包括会议通知、会议决议、 ...

Group 1: Financial Performance Expectations - The company's projected revenue for 2024 is expected to grow by 10-20% year-on-year, with a non-recurring net profit growth of 30-40% [2] - The total sales of the company's patch products in the first three quarters reached 1.169 billion yuan, an increase of 6.46% year-on-year, with sales volume increasing by 60.63% [3] - The third quarter sales total for patch products was 462 million yuan, representing a year-on-year growth of 15.57%, with sales volume increasing by 80.13% [4] Group 2: Product Development and Market Strategy - The company plans to launch new products such as Flurbiprofen gel patches and Indomethacin gel patches in the near future, which are expected to enhance the product line [3] - The company is also focusing on acquiring external formulations to strengthen its product matrix and leverage its sales network [4] - The sales of Loxoprofen sodium gel patches are minimally affected by external pricing policies, maintaining consistent pricing between hospital and retail channels [4] Group 3: Sales and Marketing Insights - The reduction in sales expense ratio is attributed to three main factors: the implementation of centralized procurement in certain regions, a transformation in the marketing model, and an increase in the share of external market sales [4] - The company emphasizes the importance of market conditions, economic environment, and industry policies on achieving its operational goals and product sales plans, highlighting the inherent uncertainties [2]